Attached files
file | filename |
---|---|
EX-99 - ACADIA PHARMACEUTICALS INC | ex99-02272018_010236.htm |
(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
On February 27, 2018, ACADIA Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2017. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
(d) The following exhibit is furnished herewith:
99.1 Press release dated February 27, 2018
ACADIA Pharmaceuticals Inc. |
By: | /s/ Glenn F. Baity |
Name: Glenn F. Baity | |
Title: Executive Vice President, General Counsel & Secretary |
Exhibit No.
|
Description
|
|
EX-99.1
|
Press release dated February 27, 2018
|